Because cannabinoid receptors are involved in these processes, particularly CB1 and CB2 receptors, it may be possible to use phytocannabinoids like THC and CBD to reduce pain associated with sickle cell disease.
The best CBD oil for sickle cell anemia will be the CBD oil that works best for you. To help you narrow down your search and find the right product, you will need to know what to look for.
CBD Oil for Pain Relief
If the desired results are not found at this amount, increase the amount by 25mg every 3 to 4 weeks until you find the effects you were after.
Using CBD oil for sickle cell anemia is not a cure. Instead, it may offer a way to make the condition more bearable.
According to Harvard University, “CBD inhibits inflammatory and neuropathic pain, two of the most difficult types of chronic pain to treat,” making it an ideal option for the severe pain associated with sickle cell anemia.
In the case of anemia, there are only a few ways that CBD oil can help; and the people with sickle cell anemia will have the most to benefit from it.
When hemoglobin isn’t manufactured correctly, we can end up with anemias such as sickle cell, and thalassemia.
This means that any damage to the red blood cells could have an effect for 3 or 4 months before a new cell is produced to replace it.
Instead, it’s probably best to stick to iron supplements and other high-concentration sources of iron, such as dark leafy vegetables, tofu, and red meat.
These opioids are a problem over the long-term because they’re highly addictive and bring with them a wide range of negative side effects. So people are now starting to use other methods of pain management for this condition such as marijuana and CBD oil.
This is a proof-of-principle investigation of the safety and potential effectiveness of inhaled vaporized cannabis when added to a stable analgesic regimen in sickle cell disease (SCD) patients with chronic pain. The study will be comprised of two 5-day intervention periods in the inpatient setting (the Clinical Research Center at SFGH), with completion of a 5-day daily pain diary prior to admission to establish an outpatient baseline. Participants will be randomly assigned, in double-blind fashion, to treatment with (A) vaporized cannabis with an approximately 1:1 ration of delta-9-tetrahydrocannabinol:cannabidiol or (B) vaporized placebo. Those who receive treatment A during the first admission will receive treatment B in the second, and those who receive treatment B during the first admission will receive treatment A in the second. The two admissions will be spaced at least 14 days apart.
Hypotheses are as follows:
Our primary objective is to assess whether inhaling vaporized cannabis ameliorates chronic pain in patients with sickle cell disease (SCD). As these patients will all be on chronic opioid analgesics, the investigators will also assess the possible synergistic affect between inhaled cannabis and opioids. The investigators will also assess the clinical safety of the concomitant use of cannabinoids and these opioids in patients with SCD by monitoring the short-term side effects associated with combined therapy. Finally, the investigators will evaluate the short-term effects of inhaled cannabis on markers of inflammation and disease progression in patients with SCD.
On Day 1 of each admission, subjects will provide blood samples for baseline markers of inflammation and SCD disease progression. They will undergo assessments of pain, mood, and quality of life. At 12 pm on Day 1, they will inhale vaporized study agent (equivalent to 1 cannabis/placebo cigarette) using the Volcano® vaporizer; on Days 2-4 they will inhale study agent at 8 am, 2 pm, and 8 pm, and they will inhale their final dose on Day 5 at 8 am. Subjects will continue their pre-study analgesic regimen while in the study. If additional analgesia is required, supplemental therapy will be administered and the dose recorded. Pain measurements by visual analogue scale will be obtained every 2 hours while subjects are awake. On Day 5 a second set of blood samples for inflammation markers and disease progression will be obtained, and subjects will again complete pain, mood, and quality of life assessments.